ARCT
$6.39
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a li...
Recent News
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics (NASDAQ:ARCT) Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA cystic fibrosis (CF) program through three Phase 2 cohorts and is preparing to initiate a longer 12-week s
Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary
Moby summary of Arcturus Therapeutics Holdings Inc.'s Q4 2025 earnings call
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call Highlights: Navigating Revenue ...
Despite a decline in revenue, Arcturus Therapeutics Holdings Inc (ARCT) extends its cash runway and achieves key regulatory approvals, signaling resilience and strategic progress.
Arcturus Therapeutics Q4 Earnings Call Highlights
Arcturus Therapeutics (NASDAQ:ARCT) executives highlighted progress across the company’s cystic fibrosis and ornithine transcarbamylase (OTC) deficiency mRNA therapeutic programs, provided updates on its partnered COVID-19 vaccine and BARDA-funded pandemic flu effort, and discussed year-over-year fi
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -11.71% and -49.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?